Endometrial Cancer Nomogram: Overall Survival Probability Following Surgery

In the U.S.

Prediction Tools: DisclaimerThe prediction tools, also known as prognostic nomograms, located on the MSK Web site are for general health information only. The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem.Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. Questions should be addressed to your own physician or other healthcare provider.MSK makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSK does not assume any risk whatsoever for your use of the prediction tools or the information contained herein. Health related information changes frequently and therefore information contained in the prediction tools may be outdated, incomplete or incorrect.Use of the prediction tools does not create an express or implied physician-patient relationship. MSK does not endorse or claim validity for the prediction tools found on the MSK Web site. The activities and products of MSK and its developers and agents (collectively MSK) are not endorsed by our past, present, or future employers. MSK does not record specific prediction tool user information and does not contact users of the prediction tools.You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. In using the prediction tools, you agree that neither MSK nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools.

Our endometrial cancer nomogram is a tool designed to predict the likelihood of survival at one year, three years, and five years after undergoing surgery to remove the endometrial (uterine) cancer.

Results produced by this tool are based on data from patients treated at MSK, a large research institution with surgeons who perform a high volume of uterine cancer procedures. This tool has been externally validated using data from large, independent sets of patients (see Supporting Publications). All results must be understood in the context of each patient’s specific treatment plan. Patients and caregivers using this tool should discuss the result with the patient’s physician.

To gather the information required to use this nomogram, use our worksheet.

Enter Your Information

All fields are required unless noted optional

How old were you when you were diagnosed with endometrial cancer? years (20 to 99)

What was the number of negative (not cancerous) lymph nodes from the pathology report? (0 to 100)

Note: Please include the number of negative nodes even if other nodes are positive.

What are lymph nodes?: Lymph nodes are rounded masses of tissue that act as filters for a fluid called lymph. Lymph nodes are located along lymphatic vessels, and they store lymphocytes (white blood cells).

What was your surgical 1988 FIGO stage?

Note: This prediction tool was created using the 1988 FIGO staging system. If your pathology report uses a later version with stages that are not included in this drop-down menu, consult with your physician for further guidance on selecting the correct stage.

More on FIGO staging: The FIGO staging system, developed by the International Federation of Gynecology and Obstetrics (FIGO), is used to stage cancers of the cervix, uterus, ovary, vagina, and vulva. It is based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.

What was your final FIGO grade?

Note: Select "grade 3" for the following tumor subtypes: serous, clear cell, and carcinosarcoma.

What is FIGO grade?: FIGO grade refers to a system developed by the International Federation of Gynecology and Obstetrics (FIGO) that describes the percentage of an endometrial tumor that is solid and not like the glands found in normal endometrium (the inner lining of the uterus).

What was the specific histologic subtype of your endometrial cancer from the pathology report?